Successful spread requires progression through several linked events rather than a single change in tumor behavior. Cancer cells must first invade nearby tissue, reach blood or lymphatic vessels, remain viable while circulating, exit at a distant site, and adapt to that organ’s microenvironment. Failure at any stage can limit the formation of a secondary tumor.
These stages determine whether disseminating cancer cells can progress beyond the primary tumor. Entry into blood or lymphatic vessels enables transport, but cells must survive circulation before leaving vessels and entering another tissue. Adaptation to the target-organ microenvironment then influences whether they can establish a secondary tumor, making each stage a distinct research focus.
Local invasion describes cancer-cell movement out of the primary tumor and into surrounding tissue, whereas vascular entry marks access to blood or lymphatic vessels. They represent separate steps that researchers can examine independently. Distinguishing them helps identify whether a factor primarily supports movement through nearby tissue, entry into the circulation, or both.
Cancer researchers combine cell-based assays, animal models, tissue analysis, and molecular profiling to examine metastatic spread. Cell-based assays can investigate behaviors such as invasion and migration, while animal models provide a broader setting for studying dissemination. Tissue analysis and molecular profiling help connect observed behavior with features of tumors or distant sites.
Studies can evaluate cancer-cell invasion, migration, vascular entry, survival during circulation, exit into new tissues, and adaptation to a target-organ microenvironment. Tissue analysis and molecular profiling add information about the cells and environments associated with these events. Together, these outcomes help researchers determine which stages promote progression toward secondary tumor formation.
Research on this process can reveal factors associated with disease progression and support the development of biomarkers. Biomarkers may help indicate metastatic activity or progression, while therapies can be designed to interfere with steps required for secondary tumor formation. This work is especially important because secondary tumors are a major cause of cancer-related mortality.